A detailed history of Lazard Asset Management LLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 154 shares of TSHA stock, worth $309. This represents 0.0% of its overall portfolio holdings.

Number of Shares
154
Previous 366 57.92%
Holding current value
$309
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.01 - $2.46 $426 - $521
-212 Reduced 57.92%
154 $0
Q2 2024

Aug 14, 2024

SELL
$2.04 - $4.17 $11,093 - $22,676
-5,438 Reduced 93.69%
366 $0
Q1 2024

May 14, 2024

SELL
$1.43 - $3.25 $4,291 - $9,753
-3,001 Reduced 34.08%
5,804 $16,000
Q4 2023

Feb 14, 2024

BUY
$1.33 - $2.88 $11,710 - $25,358
8,805 New
8,805 $15,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $97.2M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.